---
layout: full_article
title: "HEMATOLOGICAL PROFILE OF HIV/AIDS PATIENTS  AT UDAYANA UNIVERSITY HOSPITAL"
author: "Pande Visca Gayatri Prabasari, Anak Agung Wiradewi Lestari, I Nyoman Wande, I Wayan Putu Sutirta Yasa"
categories: eum
comments: true
---

<div><img src="https://jurnal.harianregional.com/media/109864-1.jpg" alt="" style="width:132pt;height:64pt;">
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<p><span class="font4">ISSN: 2597-8012 JURNAL MEDIKA UDAYANA, VOL. 13 NO.01, JANUARI, 2024</span></p>
</div><br clear="all">
<div><img src="https://jurnal.harianregional.com/media/109864-2.jpg" alt="" style="width:90pt;height:15pt;">
</div><br clear="all">
<div><img src="https://jurnal.harianregional.com/media/109864-3.jpg" alt="" style="width:78pt;height:20pt;">
</div><br clear="all">
<div>
<p><span class="font4">Received: 2023-11-29Revision: 2023-11- 30 Accepted: 25-12-2023</span></p>
</div><br clear="all">
<p><span class="font5" style="font-weight:bold;">HEMATOLOGICAL PROFILE OF HIV/AIDS PATIENTS AT UDAYANA UNIVERSITY HOSPITAL</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font6" style="font-weight:bold;"><a name="bookmark1"></a>Pande Visca Gayatri Prabasari<sup>1</sup>, Anak Agung Wiradewi Lestari<sup>2</sup>, I Nyoman Wande<sup>2</sup>, I Wayan Putu Sutirta Yasa<sup>2</sup></span></h1>
<p><span class="font5"><sup>1</sup>The Undergraduate Medical Study Program, Faculty of Medicine, Udayana University, Bali <sup>2</sup>Departement of Clinical Pathology, Faculty of Medicine, Udayana University, Bali Correspondence: Pande Visca Gayatri Prabasari</span></p>
<p><span class="font5">E-mail:</span><a href="mailto:viscagayatri1303@gmail.com"><span class="font5"> </span><span class="font5" style="text-decoration:underline;">viscagayatri1303@gmail.com</span></a></p>
<p><span class="font5" style="font-weight:bold;">ABSTRACT</span></p>
<p><span class="font5">Human Immunodeficiency Virus (HIV) is a virus that will enter the body and infect white blood cells (lymphocytes), causing human immunity to decrease. Acquired Immune Deficiency Syndrome (AIDS) is the final stage that will appear after the HIV virus attacks the immune system, causing variety symptoms. One of the complications that can be found in HIV/AIDS is hematological abnormalities such as anemia, thrombocytopenia, leukopenia and lymphopenia due to impaired hematopoietic caused by viral infection that can disrupt the quality of life of patients. The aims of this research to determine the hematological profile of people with HIV/AIDS such as the prevalence of anemia, thrombocytopenia, leukopenia, and lymphopenia. This research used a descriptive method with a cross-sectional study. Data collection was conducted using medical records from Udayana University Hospital based on established inclusion and exclusion criteria. The results obtained from 31 people diagnosed with HIV/AIDS showed the majorities were male, in the age group of 18-39 years and most were diagnosed with stage IV. The research showed that hemoglobin levels and lymphocyte percentages mostly decreased, while leukocyte counts and platelet counts were in the normal range. Based on age, the highest proportion of anemia, thrombocytopenia, leukopenia and lymphopenia occurs in the 40-59 age group.</span></p>
<p><span class="font5" style="font-weight:bold;">Keywords</span><span class="font5">: HIV/AIDS, hematological abnormalities, hematological profile</span></p>
<h2><a name="bookmark2"></a><span class="font4" style="font-weight:bold;"><a name="bookmark3"></a>INTRODUCTION</span></h2>
<p><span class="font4">Human Immunodeficiency Virus (HIV) is a virus that can enter the human body through blood, vaginal fluid, or semen. The HIV virus will infect white blood cells (lymphocyte), which can cause human immunity to decrease. Acquired Immune Deficiency Syndrome (AIDS) is the final stage that appears after the HIV virus attacks the body's immune system and causes symptoms that last for years.<sup>1</sup> The number of HIV/AIDS cases continued to increase until they finally spread to all countries in the world. At the end of 2017, there were 36.90 million sufferers found in the world.<sup>2</sup> According to the annual HIV report up to March 2021, there were 568.618 people living with HIV/AIDS in Indonesia</span><span class="font1">.</span><span class="font4"><sup>3</sup> HIV/AIDS cases can also be found in Bali, where there were 26.519 people living with HIV/AIDS in March</span><span class="font1">.</span><span class="font4"><sup>4</sup> Early HIV/AIDS screening is important because it allows for early treatment, which can help to prevent the progression of the disease and improve the clinical condition of the patient.<sup>5</sup></span></p>
<p><span class="font4">One of the initial evaluations that can be done by people living with HIV/AIDS is laboratory tests, such as hematological examination. The hematological profile of people living with HIV/AIDS can be used as a prognostic</span></p>
<p><span class="font4">factor due to hematological abnormalities. Hematological abnormalities is one of the clinical manifestations that can be found in people living with HIV/AIDS, especially in advanced stages<sup>.6</sup> Hematological abnormalities found is cytopenia (decreasing one type of blood cell) such as anemia, leukopenia and thrombocytopenia. The cause of hematological abnormalities in HIV/AIDS is due to impaired hematopoietic caused by viral infection, which leads to decrease in the number of blood cells. The occurrence of hematopoietic dysfunction is characterized by progressive damage and suppression of the function hematopoietic progenitor stem cells (HSPCs) by viral infection, leading to clinical manifestations in the form of cytopenia.<sup>7</sup></span></p>
<p><span class="font4">Hematological abnormalities can be impaired the quality of life of the patient or be life threatening if not treated properly.<sup>7</sup> Therefore, hematological examination should be performed to monitor any changes in all blood cell lineages during HIV infection. Hematological examination also aims to provide the necessary clinical interventions to prevent complications and other comorbidities.<sup>8</sup></span></p>
<p><span class="font4">Based on the problems that have been explained, this research was conducted to look at the hematological profile</span></p>
<p><span class="font3">HEMATOLOGICAL PROFILE OF HIV/AIDS PATIENTS AT UDAYANA UNIVERSITY HOSPITAL.. Pande Visca Gayatri Prabasari1, Anak Agung Wiradewi Lestari2, I Nyoman Wande2, I Wayan Putu Sutirta Yasa2</span></p>
<p><span class="font4">such as hemoglobin, leukocyte, lymphocyte and platelet in people with HIV/AIDS at Udayana University Hospital from January 2022 to June 2023.</span></p>
<h2><a name="bookmark4"></a><span class="font4" style="font-weight:bold;"><a name="bookmark5"></a>MATERIAL AND METHOD</span></h2>
<p><span class="font4">This research is a descriptive study with a cross-sectional design. This research was carried out in the medical records room at Udayana University Hospital. The target population for this research is people with HIV/AIDS at Udayana University Hospital and the study population is people with HIV/AIDS at Udayana University Hospital from January 2022 to June 2023. The inclusion criteria for this research are patients who have been diagnosed with HIV infection and have undergone hematological examination (hemoglobin, platelet, leukocyte, and lymphocyte) for the first time, as</span></p>
<p><span class="font4">recorded in the medical records of Udayana University Hospital from January 2022 to June 2023. The exclusion criteria were patients with incomplete medical records (no hematology examination results sheet) and who did not meet the variables to be studied.</span></p>
<p><span class="font4">The research process began with making a proposal, requesting permission from the ethics committee of the Faculty Medicine Udayana University and preparing an extraction form to retrieve medical record data. The data collected based on the inclusion and exclusion criteria will be processed and analyzed using SPSS version 26 to determine the frequency distribution and percentage of each variable that has been studied. This research has been approved by the Ethics Committee of the Faculty Medicine Udayana University with the letter number 217/UN14.2.2.VII.14/LT/2023.</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">RESULT</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">Table 1. </span><span class="font4">Frequency Distribution Characteristics Respondents</span></p>
<p><span class="font4" style="font-weight:bold;">Characteristics Respondents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Frequency (n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentages (%)</span></p>
<p><span class="font4" style="font-weight:bold;">Gender</span></p>
<p><span class="font4">Male &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;71%</span></p>
<p><span class="font4">Female &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29%</span></p>
<p><span class="font4" style="font-weight:bold;">Age</span></p>
<p><span class="font4">18 – 39 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.1%</span></p>
<p><span class="font4">40 – 59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41.9%</span></p>
<p><span class="font4">&gt;60 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13%</span></p>
<p><span class="font4" style="font-weight:bold;">Stadium</span></p>
<p><span class="font4">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0%</span></p>
<p><span class="font4">II &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.9%</span></p>
<p><span class="font4">III &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2%</span></p>
<p><span class="font4">IV &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;83.9%</span></p>
<p><span class="font4" style="font-weight:bold;">Total &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font4">31 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100%</span></p></td></tr>
</table>
<p><span class="font4">Based on Table 1. this study consisted of 31 people &nbsp;&nbsp;&nbsp;(45.1%), followed by the 40-59 age group, with 13 people</span></p>
<p><span class="font4">that met the inclusion criteria. Other samples included to &nbsp;&nbsp;&nbsp;(41.9%), and the &gt;60 age group, with 4 people (13%). The</span></p>
<p><span class="font4">exclusion criteria due to incomplete medical record data. &nbsp;&nbsp;&nbsp;majority of HIV patient, 26 people (83.9%) was diagnosed</span></p>
<p><span class="font4">There were 22 people (71%) with male sex and 9 people &nbsp;&nbsp;&nbsp;at stage IV. Followed by stage II with 4 people (12.9%),</span></p>
<p><span class="font4">(29%) with female sex. Based on age group, the majority of &nbsp;&nbsp;&nbsp;stage III with 1 person (3.2%), and no patient in stage I.</span></p>
<p><span class="font4">cases occurred in the 18-39 age group, with 13 people</span></p>
<table border="1">
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">Table 2. </span><span class="font4">Frequency Distribution of Hematological Profile in HIV/AIDS Patients</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Hematological Profile</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Frequency (n)</span></p></td><td style="vertical-align:top;">
<p><span class="font4" style="font-weight:bold;">Percentages (%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">Hemoglobin</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Low</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">20</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">64.5%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Normal</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">11</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">35.5%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">High</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">0%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4" style="font-weight:bold;">Platelet</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Low</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">3.2%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Normal</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">30</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">96.8%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">High</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">100%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">Leukocyte</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Low</span></p></td><td style="vertical-align:top;">
<p><span class="font4">5</span></p></td><td style="vertical-align:top;">
<p><span class="font4">16.1%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Normal</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">22</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">71%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">High</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">4</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">12.9%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">Lymphocyte</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Low</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">17</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">54.8%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Normal</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">13</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">41.9%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">High</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">3.2%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4" style="font-weight:bold;">Total</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">31</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">100%</span></p></td></tr>
</table>
<p><span class="font4">Based on Table 2. the results of this study showed 20 people (64.5%) with decreased hemoglobin levels. Only 11 people (35.5%) with normal hemoglobin levels. No patient with increased hemoglobin levels.</span></p>
<p><span class="font4">There are 30 people (96.8%) with normal platelet counts. Only 1 person (3.2%) with decreased platelet counts, and no patient with increased platelet counts.</span></p>
<p><span class="font4">Most of the samples, 22 people (71%), showed normal leukocyte counts. Only 5 people (16.1%) with decreased</span></p>
<p><span class="font4">leukocyte counts and 4 people (12.9%) with increased leukocyte counts.</span></p>
<p><span class="font4">The result of the study showed that most of the samples, 17 people (54.8%), had decreased lymphocyte percentages. Only 13 (41.9%) people with normal lymphocyte percentages and 1 (3.2%) person with increased lymphocyte percentages</span><span class="font2">.</span></p>
<p><span class="font4" style="font-weight:bold;">Table 3. </span><span class="font4">Proportion Distribution Cytop</span><span class="font4" style="text-decoration:underline;">enia Based on Age in</span><span class="font4"> HIV/AIDS Patients</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font4" style="font-weight:bold;">Hematological Profile</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4" style="font-weight:bold;">18 – 39 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 – 59 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;60 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</span></p>
<p><span class="font4" style="font-weight:bold;">(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(%) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(%) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(%) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(%)</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Anemia</span></p>
<p><span class="font4">Thrombocytopenia Leukopenia Lymphopenia</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15% &nbsp;&nbsp;&nbsp;&nbsp;20 &nbsp;&nbsp;&nbsp;&nbsp;100%</span></p>
<p><span class="font4">0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100% &nbsp;&nbsp;&nbsp;&nbsp;0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;100%</span></p>
<p><span class="font4">0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font5">3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font4">60% &nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font5">2 &nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font4">40% &nbsp;&nbsp;&nbsp;&nbsp;5 &nbsp;&nbsp;&nbsp;&nbsp;100%</span></p>
<p><span class="font4">6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.3% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;11.7% &nbsp;&nbsp;&nbsp;&nbsp;17 &nbsp;&nbsp;&nbsp;&nbsp;100%</span></p></td></tr>
</table>
<p><span class="font4">Based on table 3. the proportion of anemia, leukopenia and lymphopenia mostly in the age group of 40 – 59, respectively 10 (50%), 3 (60%) and 9 (53%) people. The proportion of thrombocytopenia only found in the 40 – 59 age group, with 1 person (100%).</span></p>
<h2><a name="bookmark6"></a><span class="font4" style="font-weight:bold;"><a name="bookmark7"></a>DISCUSSION</span></h2>
<p><span class="font4">This research was conducted to determine the hematological profile of HIV/AIDS patients at Udayana University Hospital. Based on this research, of the 31 people with HIV/AIDS the majority were male with 22 people (71%). This is appropriate with the research conducted by Umar, which found that the majority of HIV/AIDS cases are in male. One of the reasons why the number of males with </span><a href="http://ojs.unud.ac.id/index.php/eum"><span class="font1">http://ojs.unud.ac.id/index.php/eum</span></a><span class="font1"> doi:10.24843.MU.2024.V13.i01.P13</span></p>
<p><span class="font4">HIV/AIDS is high because of homosexual contact between HIV-infected individuals, both with other HIV-infected individuals and with those who are not yet infected with HIV.<sup>9</sup> In addition, this study is also supported by the theory that homosexual contact has a 1.97 times higher risk of HIV infection than heterosexual contact.<sup>10</sup></span></p>
<p><span class="font4">Based on age, the most cases of HIV/AIDS occurred in the 18-39 age group, with 14 people (45.1%). The difference was only 1 sample in the 40-59 age group, with 13 people (41.9%). According to the theory explained by Novita, people with age &lt;40 years are 7.2 times more likely to be infected with HIV/AIDS than people with age &gt;40 years. This is because people with age &lt;40 years are classified as productive years, where their social interactions</span></p>
<p><span class="font4">and lifestyles are relatively free. This can lead to an increased risk of HIV/AIDS infection.<sup>11</sup> If many cases of HIV/AIDS are in the &gt;50 age group, it is because education about HIV/AIDS is more focused on younger generations, so the understanding about the risk of HIV/AIDS infection is lower in the &gt;50 age group.<sup>12</sup></span></p>
<p><span class="font4">The majority of HIV stages were diagnosed at stage IV, with 26 people (83.9%). Stage IV is the final stage of HIV, where the patient has already entered into AIDS. There are many factors that can contribute to the rapid progression of HIV to stage IV, including delayed diagnosis, stigma, and social discrimination, which can lead to patients hiding their illness and not seeking treatment.<sup>13</sup></span></p>
<p><span class="font4">Anemia is one of the most common hematological abnormalities found in people with HIV/AIDS. Anemia can increase mortality and morbidity in HIV infection.<sup>14</sup> This theory is supported by the findings of this research, which found that anemia was the most common hematological abnormalities, with a prevalence of 64.5%. This research is appropriate with research conducted at RSU Bandung Medan, which found mostly had anemia, with 23 of 43 people.<sup>14</sup> Anemia in HIV/AIDS is caused by three main factors such as decreased red blood cell production, increased red blood cell destruction, and infection of red blood cell production.<sup>15</sup> As age increases, the risk of anemia increases too, from 37.4% in people aged 35 to 46% in people aged 46 and over.<sup>16</sup> The proportion of anemia in this study was highest in the 40-59 age group, at 50%. This trend is appropriate with the general finding that the incidence of anemia increases with age. However, there was a slight decrease in the &gt;60 age group.</span></p>
<p><span class="font4">People with HIV/AIDS who undergone platelet counts examinations generally showed normal results, with 30 people (96.8%). This research is appropriate with research conducted at City of Yaoundé, found that platelet counts were mostly normal at 80.65%.<sup>17</sup> The research conducted by Ayanaw et al also found that platelet counts were mostly normal at 88.4%.<sup>18</sup> A theory suggests that high serum thrombopoietin levels in people with HIV/AIDS may help to maintain normal platelet counts.<sup>8</sup> If thrombocytopenia is found, it is one of the complications caused by an immune mechanism that results in the clearance of platelets by the reticuloendothelial system.<sup>19</sup> In this research, the prevalence of thrombocytopenia was found at 2.9%. The presence of myelodysplasia in people with age &gt;40 years can also cause thrombocytopenia.<sup>20</sup> The theory is appropriate with this research, where the incidence of thrombocytopenia was found in the 40-59 age group.</span></p>
<p><span class="font4">This result research found that leukocyte counts were mostly normal, with 22 people (71%). These results is appropriate with the findings of a research conducted by Kothari et al which found that leukocyte counts were mostly normal at 85% compared to leukopenia or leukocytosis.<sup>21 </sup>The research result are also appropriate with other conducted at RSUD Koja, which found that leukocyte counts were mostly within the normal range.<sup>22</sup> If the HIV </span><a href="http://ojs.unud.ac.id/index.php/eum"><span class="font1">http://ojs.unud.ac.id/index.php/eum</span></a><span class="font1"> doi:10.24843.MU.2024.V13.i01.P13</span></p>
<p><span class="font4">infection has not yet caused bone marrow suppression, which will lead to a decrease in granulocyte stimulating factor, then leukocyte counts will remain in normal range. In addition, antiretroviral therapy can help maintain the number of leukocyte counts in the normal range. However, antiretroviral therapy can also cause leukopenia.<sup>23</sup> It can be said, that theory is appropriate to the findings of this research, which found that the prevalence of leukopenia was 16.1%. This can be influenced by various factors, such as patient compliance with treatment and the patient's overall health condition. This research showed that, as age increases, the risk of leukopenia increases too. This can be influenced by natural aging which causes the function of the immune system to decrease, causing the production and decreased response of white blood cells.<sup>24</sup></span></p>
<p><span class="font4">Based on the lymphocyte percentages examination, mostly decreased with the prevalence of 54.8%. The research by Amran &amp;&nbsp;Al Qarni found that 73.33% of patients most experienced a decrease in lymphocytes, which is appropriate with the results of this research.<sup>25</sup> The research by Soraya &amp;&nbsp;Artika also found that most patients experienced a decrease in lymphocyte percentages, specifically 48.1%.<sup>26</sup> Lymphopenia occurs in HIV/AIDS because it involves CD4 T helper cells and is considered a primary indication of HIV infection, where HIV infection will infect and destroy CD4 Helper T lymphocyte cells gradually so the immune system in the body will decrease and unable to fight HIV infection until the lymphocyte cells in the blood decrease.<sup>6</sup> Based on age, lymphopenia is mostly in the age group of 40 – 59 years, this can happen because of thymic involution associated with increasing age, which leads decrease in the production of T lymphocytes. This generally begins to occur when the patient reaches the age of ≥ 45 years.<sup>27</sup></span></p>
<h2><a name="bookmark8"></a><span class="font4" style="font-weight:bold;"><a name="bookmark9"></a>CONCLUSIONS AND SUGGESTION</span></h2>
<p><span class="font4">Based on the research, showed that the prevalence of anemia and lymphopenia was more common than the prevalence of leukopenia and thrombocytopenia in people with HIV/AIDS. As age increases, the risk of anemia, thrombocytopenia, leukopenia, and lymphopenia increases too, mostly in the 40 – 59 age group. However, there is a decrease in the &gt;60 age group.</span></p>
<p><span class="font4">Hematological examinations are important for HIV/AIDS patients to prevent severity, complications, and even death by providing appropriate management according to the results of hematological examinations. In addition, it is hoped that future research will be able to provide more information about the relationship between hematological parameter variables and other variables such as patient nutritional status, HIV stage, and patient ARV treatment history with a larger sample size</span></p>
<h2><a name="bookmark10"></a><span class="font4" style="font-weight:bold;"><a name="bookmark11"></a>REFERENCES</span></h2>
<ul style="list-style:none;"><li>
<p><span class="font4">1. &nbsp;&nbsp;&nbsp;Ersha RF, Ahmad A. Human Immunodeficiency Virus – Acquired Immunodeficiency Syndrome dengan Sarkoma Kaposi. J Kesehat Andalas. 2018;7(Supplement 3):131.</span></p></li>
<li>
<p><span class="font4">2. &nbsp;&nbsp;&nbsp;Regina F, Manopo R. Upaya United Nations Programme on Aids (Unaids) Dalam Mengakhiri Epidemi Hiv / Aids Di Indonesia Melalui Fast Track Strategy Tahun 20152018. Fast Track Strateg United Nations Program AIDS sebagai Organ Int yang Berger dibidang Kesehat khususnya HIV/AIDS. 2018;1–10.</span></p></li>
<li>
<p><span class="font0">3.</span><span class="font4"> &nbsp;&nbsp;&nbsp;Afriana N, Luhukay L, Mulyani PS, Irmawati, Romauli, Pratono, et al. Laporan Tahunan HIV AIDS 2022 Kemenkes. &nbsp;&nbsp;&nbsp;&nbsp;2022;1–91. &nbsp;&nbsp;&nbsp;&nbsp;Available &nbsp;&nbsp;&nbsp;&nbsp;from:</span></p></li></ul>
<p><a href="http://p2p.kemkes.go.id/wp-content/uploads/2023/06/FINAL_6072023_Layout_HIVAIDS-1.pdf"><span class="font4">http://p2p.kemkes.go.id/wp-</span></a></p>
<p><a href="http://p2p.kemkes.go.id/wp-content/uploads/2023/06/FINAL_6072023_Layout_HIVAIDS-1.pdf"><span class="font4">content/uploads/2023/06/FINAL_6072023_Layout_HIV</span></a><span class="font4"> </span><a href="http://p2p.kemkes.go.id/wp-content/uploads/2023/06/FINAL_6072023_Layout_HIVAIDS-1.pdf"><span class="font4">AIDS-1.pdf</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font4">4. &nbsp;&nbsp;&nbsp;Dinkes Bali. Bali Terbebas HIV/AIDS 2030. Dinas Kesehatan Provinsi Bali. 2022. Available from: </span><a href="https://diskes.baliprov.go.id/bali-terbebas-hiv-aids-2030"><span class="font4">https://diskes.baliprov.go.id/bali-terbebas-hiv-aids-2030</span></a></p></li>
<li>
<p><span class="font4">5. &nbsp;&nbsp;&nbsp;Krisnahari KL, Sawitri AAS. Karakteristik Pasien HIV/AIDS dengan Koinfeksi Tuberkulosis di Rumah Sakit Umum Daerah (RSUD) Badung dan Klinik Bali Medika Kuta. E-Jurnal Med Udayana [Internet]. 2018;7(11):1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Available &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from:</span></p></li></ul>
<p><a href="https://ojs.unud.ac.id/index.php/eum/article/view/44090"><span class="font4">https://ojs.unud.ac.id/index.php/eum/article/view/44090</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font4">6. &nbsp;&nbsp;&nbsp;Bhardwaj S, Almaeen A, Ahmed Wani F, Thirunavukkarasu A. Hematologic derangements in HIV/AIDS patients and their relationship with the CD4 counts: a cross-sectional study. Int J Clin Exp Pathol [Internet]. 2020;13(4):756–63. Available from: </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/32355524&#xa;http:/www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7191136"><span class="font4">http://www.ncbi.nlm.nih.gov/pubmed/32355524%0Ahtt</span></a><span class="font4"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/32355524&#xa;http:/www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7191136"><span class="font4">p://www.pubmedcentral.nih.gov</span><span class="font0">/</span><span class="font4">articlerender.fcgi?artid</span></a><span class="font4"> </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/32355524&#xa;http:/www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7191136"><span class="font4">=PMC7191136</span></a></p></li>
<li>
<p><span class="font4">7. &nbsp;&nbsp;&nbsp;Durandt C, Potgieter JC, Mellet J, Herd C, Khoosal R, Nel JG, et al. HIV and haematopoiesis. S Afr Med J. 2019;109(8):40–5.</span></p></li>
<li>
<p><span class="font4">8. &nbsp;&nbsp;&nbsp;Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2021;13(2):98– 109.</span></p></li>
<li>
<p><span class="font4">9. &nbsp;&nbsp;&nbsp;Umar H, Umar A. Gambaran Kadar Hemoglobin Pada Penderita Hiv Dengan Pengobatan Antiretroviral Di Kota Kendari. J Anal Kesehat Kendari. 2021;4(1):7–13.</span></p></li>
<li>
<p><span class="font4">10. &nbsp;&nbsp;&nbsp;Rohmatullailah D, Fikriyah D. Faktor Risiko Kejadian HIV Pada Kelompok Usia Produktif di Indonesia. J Biostat Kependudukan, dan Inform Kesehat. 2021;2(1):45.</span></p></li>
<li>
<p><span class="font4">11. &nbsp;&nbsp;&nbsp;Novita Y. Faktor – Faktor Yang Berhubungan Dengan Kejadian Sekolah Tinggi Ilmu Kesehatan Medika Cikarang Tahun 2018. Fakt Yang Berhubungan Dengan Kejadian &nbsp;&nbsp;&nbsp;Hiv/Aids &nbsp;&nbsp;&nbsp;Di &nbsp;&nbsp;&nbsp;Rsud &nbsp;&nbsp;&nbsp;Kabupaten</span></p></li></ul>
<p><span class="font4">Bekasi.2018;(2):1</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">12. &nbsp;&nbsp;&nbsp;Kiplagat J, Mwangi A, Chasela C, Huschke S. Challenges with seeking HIV care services: Perspectives of older adults infected with HIV in western Kenya.</span></p></li></ul>
<p><span class="font4">BMC Public Health. 2019;19(1):1–12.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">13. &nbsp;&nbsp;&nbsp;Puspasari D, Wisaksana R, Ruslami R. Gambaran Efek Samping dan Kepatuhan Terapi Antiretroviral pada Pasien HIV di Rumah Sakit Dr. Hasan Sadikin Bandung Tahun 2015 in HIV Patients at Dr. Hasan Sadikin Hospital in 2015. Jsk. 2018;3(4):175–81.</span></p></li>
<li>
<p><span class="font4">14. &nbsp;&nbsp;&nbsp;Wiratma DY, Aruan DGR. Profil Kadar Hemoglobin Pasien Human Immunodeficiency Virus (Hiv) Di Rsu Bandung Medan. Anat Med J | Amj. 2020;3(3):175.</span></p></li>
<li>
<p><span class="font4">15. &nbsp;&nbsp;&nbsp;Ibrahim K, Kurnia H Y, Rahayuwati L, Nurmalisa BE, Rifa’atul Fitri SU. Hubungan antara Fatigue, Jumlah CD4, dan Kadar Hemoglobin pada Pasien yang Terinfeksi Human Immunodeficiency Virus (HIV). J Keperawatan Padjadjaran. 2018;5(3).</span></p></li>
<li>
<p><span class="font4">16. &nbsp;&nbsp;&nbsp;Defiaroza. Analisis Kadar Haemoglobin (Hb) Pasien HIV/AIDS Di Yayasan Lantera Minangkabau Padang Tahun 2017. J Menara Ilmu. 2018;XII (6):79–88.</span></p></li>
<li>
<p><span class="font4">17. &nbsp;&nbsp;&nbsp;Nka AD, Sosso SM, Fokam J, Bouba Y, Teto G, Simo Rachel R, et al. Thrombocytopenia according to antiretroviral drug combinations, viremia and CD4 lymphocytes among HIV-infected patients in Cameroon: A snapshot from the City of Yaoundé. BMC Res Notes [Internet]. &nbsp;&nbsp;&nbsp;&nbsp;2019;12(1):1–5. &nbsp;&nbsp;&nbsp;&nbsp;Available &nbsp;&nbsp;&nbsp;&nbsp;from:</span></p></li></ul>
<p><a href="https://doi.org/10.1186/s13104-019-4664-7"><span class="font4">https://doi.org/10.1186/s13104-019-4664-7</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font4">18. &nbsp;&nbsp;&nbsp;Ayanaw MA, Yabeyu AB, Lenjiso G, Kifle ZD. Prevalence and predictors of thrombocytopenia among HAART naive HIV positive patients at Ambo University Referral Hospital. Clin Epidemiol Glob Heal [Internet]. 2022;15(February):101049. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Available &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from:</span></p></li></ul>
<p><a href="https://doi.org/10.1016/j.cegh.2022.101049"><span class="font4">https://doi.org/10.1016/j.cegh.2022.101049</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font4">19. &nbsp;&nbsp;&nbsp;Wiraguna I. Faktor-Faktor Yang Mempengaruhi Abnormalitas Hematologi Pasien Infeksi Human Immunodeficiency Virus (Hiv) Di Rumah Sakit Wahidin Sudirohusodo &nbsp;&nbsp;&nbsp;Makassar= &nbsp;&nbsp;&nbsp;Factors &nbsp;&nbsp;&nbsp;Affected</span></p></li></ul>
<p><span class="font4">Hematological Abnormality In HIV Infection Patients At Wahidin Sudirohusodo Hospital Makassar. 2022. (Doctoral dissertation, Universitas Hasanuddin). Available &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from:</span></p>
<p><a href="http://repository.unhas.ac.id/id/eprint/21894/"><span class="font4">http://repository.unhas.ac.id/id/eprint/21894/</span></a></p>
<ul style="list-style:none;"><li>
<p><span class="font4">20. &nbsp;&nbsp;&nbsp;Xiaoyan Lv, Li P, Yue P, Tang P, Zhou F. Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS. Ther Adv Hematol. 2023;14:1–14.</span></p></li>
<li>
<p><span class="font4">21. &nbsp;&nbsp;&nbsp;Kothari R, Bhalara R, Dave R, Dhruva G. Haematological Profile In HIV Infected Patients With Comparison To CD4 Haematological Profile In HIV Infected Patients With Comparison To CD4 Count. 2022;(May).</span></p></li>
<li>
<p><span class="font4">22. &nbsp;&nbsp;&nbsp;Hilman CC, Ndraha S. Profil Penderita HIV / AIDS di RSUD Koja. J Kedokt Meditek. 2019;25(2):81–7.</span></p></li>
<li>
<p><span class="font4">23. &nbsp;&nbsp;&nbsp;Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17:s2–104.</span></p></li>
<li>
<p><span class="font4">24. &nbsp;&nbsp;&nbsp;Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a Cause of Immune Activation and Immunosenescence. Mediators Inflamm. 2017;2017(Il).</span></p></li>
<li>
<p><span class="font4">25. &nbsp;&nbsp;&nbsp;Amran P, Al Qarni AW. Analisis Jumlah Pemeriksaan Limfosit Pada Penderita Human Immunodefisiency Virus (Hiv). J Media Anal Kesehat. 2019;10(1):28.</span></p></li>
<li>
<p><span class="font4">26. &nbsp;&nbsp;&nbsp;Soraya DAH, Artika DM. Profil Pasien Koinfeksi TB-HIV Di Rumah Sakit Umum Pusat Sanglah Bali Tahun 2013. E-Jurnal Med. 2016;5(7):1–5.</span></p></li>
<li>
<p><span class="font4">27. &nbsp;&nbsp;&nbsp;Mpondo BCT. HIV Infection in the Elderly: Arising Challenges. J Aging Res. 2016;2016</span></p><img src="https://jurnal.harianregional.com/media/109864-4.jpg" alt="" style="width:66pt;height:24pt;"></li></ul>
<p><a href="http://ojs.unud.ac.id/index.php/eum"><span class="font1">http://ojs.unud.ac.id/index.php/eum</span></a></p>
<p><span class="font1">doi:10.24843.MU.2024.V13.i01.P13</span></p>
<p><span class="font1">P a g e 64</span></p>